185 related articles for article (PubMed ID: 38429789)
41. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
[TBL] [Abstract][Full Text] [Related]
42. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
Yousefi H; Khosla M; Lauterboeck L; Okpechi SC; Worthylake D; Garai J; Zabaleta J; Guidry J; Zarandi MA; Wyczechowska D; Jayawickramarajah J; Yang Q; Kissil J; Alahari SK
Oncogene; 2022 Nov; 41(47):5076-5091. PubMed ID: 36243802
[TBL] [Abstract][Full Text] [Related]
43. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
44. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
45. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
46. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
47. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer.
Dowling CM; Hollinshead KER; Di Grande A; Pritchard J; Zhang H; Dillon ET; Haley K; Papadopoulos E; Mehta AK; Bleach R; Lindner AU; Mooney B; Düssmann H; O'Connor D; Prehn JHM; Wynne K; Hemann M; Bradner JE; Kimmelman AC; Guerriero JL; Cagney G; Wong KK; Letai AG; Chonghaile TN
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523897
[TBL] [Abstract][Full Text] [Related]
48. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
49. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
Zhuang F; Huang S; Liu L
Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
[TBL] [Abstract][Full Text] [Related]
50. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
Tang M; O'Grady S; Crown J; Duffy MJ
Breast Cancer Res Treat; 2022 Sep; 195(2):105-115. PubMed ID: 35908121
[TBL] [Abstract][Full Text] [Related]
51. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
52. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
53. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
54. OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.
Wu M; Huang Q; Liao M; Wu X; Xi H; Ma H; Li S; Zhang Y; Xia Y
Cell Oncol (Dordr); 2022 Dec; 45(6):1255-1275. PubMed ID: 36155886
[TBL] [Abstract][Full Text] [Related]
55. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
57. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
[No Abstract] [Full Text] [Related]
59. Cytotoxic evaluation of YSL-109 in a triple negative breast cancer cell line and toxicological evaluations.
Sixto-López Y; Ordaz-Pichardo C; Gómez-Vidal JA; Rosales-Hernández MC; Correa-Basurto J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jun; 396(6):1211-1222. PubMed ID: 36694011
[TBL] [Abstract][Full Text] [Related]
60. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]